Moderna Announces Free mRNA Course
The pharmaceutical company worked with Coursera to develop the three-module course.
Stock.adobe.com
Moderna announced the launch of a three-module course titled mRNAs as Medicines.1 Developed in partnership with Coursera, the course provides education on how mRNA medicines work, how they’re developed, and potential use-cases.
According to a press release from Moderna, the inspiration for the course was two-fold. First, it was designed to provide a general knowledge base to the population about an emerging biotechnology. Second, it will help advance scientific education to those interested in pursuing a STEM career.
In a press release, Moderna’s chief human resources officer Tracey Franklin said, “At Moderna, we obsess over learning and believe when education is accessible, it can transform our lives and communities. By partnering with Coursera to offer this free course to everyone, we can help people deepen their understanding of mRNA science, how it represents a new era of medicine, and its power to positively impact human health."
In the same press release, Coursera chief content officer Marni Baker-Stein said, “We're excited to welcome Moderna to the Coursera platform as the demand for STEM skills continues to grow around the world. By offering the ‘mRNAs as Medicines' course for free, we are empowering learners worldwide to gain an in-depth understanding of the revolutionary and life-saving mRNA technology directly from Moderna experts. This initiative not only supports current and aspiring medical professionals, it makes it easier and more affordable for anyone to start their learning journey in this critical field."
In July, Moderna announced that it had entered into an agreement with Mitsubishi Tanabe Pharma Corporation to promote Moderna’s mRNA respiratory vaccine portfolio in Japan.2
In a press release issued at the time, Moderna Japan’s president and representative director Kazumasa Nagayama said, “We are pleased to partner with Mitsubishi Tanabe Pharma to enable the commercialization of our COVID-19 vaccine and future mRNA respiratory vaccine portfolio to the people of Japan. Mitsubishi Tanabe Pharma has a significant heritage in Japan and has long contributed to public health through numerous vaccines and possesses extensive experience and deep knowledge in this area. We look forward to working together to provide our COVID-19 vaccine in Japan, given the virus continues to pose a significant threat to public health."
In the same press release Mitsubishi Tanaba Pharma representative director Akihiro Tsujimura said, “Moderna has delivered COVID-19 vaccines to many people worldwide since the COVID-19 pandemic began. We are delighted to collaborate with Moderna and engage in commercial activities for the COVID-19 vaccine and other mRNA respiratory vaccines in Japan. We will continue to contribute to public health in Japan through our vaccine business."
Also in July, Moderna announced that David Rubinstein would join its board of directors in early August.3
In a press release, Rubenstein said, “I am honored to join the Board of Directors at Moderna, a company at the forefront of medical innovation and biotechnology. Moderna's commitment to groundbreaking research and its role in addressing global health challenges align deeply with my passion for advancing scientific progress and improving lives. I look forward to contributing to the continued success and transformative impact of this remarkable organization."
Source
- Moderna and Coursera Launch Free Course on mRNA Technology. Moderna. August 14, 2024. https://investors.modernatx.com/news/news-details/2024/Moderna-and-Coursera-Launch-Free-Course-on-mRNA-Technology/default.aspx
- Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines. Moderna. July 8, 2024. Accessed August 19, 2024. https://investors.modernatx.com/news/news-details/2024/Moderna-And-Mitsubishi-Tanabe-Pharma-Corporation-Enter-Joint-Agreement-to-Promote-Modernas-mRNA-Respiratory-Vaccine-Portfolio-in-Japan-Including-COVID-19-Vaccines/default.aspx
- David Rubenstein Joins Moderna's Board of Directors. Moderna. July 23, 2024. Accessed August 19, 2024. https://investors.modernatx.com/news/news-details/2024/David-Rubenstein-Joins-Modernas-Board-of-Directors/default.aspx
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
